Clinical Trials on Essential Tremor in Belgium

Total 222 results

KU Leuven

Completed

The Trans-cutaneous Effects on Physiological Tremor Entertainment During tACS

Tremor, Limb

Belgium
Myles Mc Laughlin

Completed

Interphase Gap in Biphasic Stimulation in DBS for ET

Essential Tremor

Belgium
Boston Scientific Corporation

Recruiting

Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)

Essential Tremor

Germany, Korea, Republic of, Canada, Belgium, Hungary, Spain, Portugal, Italy
KU Leuven

Completed

Investigating the Use of Complex Pulse Shapes for DBS in Movement Disorders (INSHAPE_DBS)

Parkinson Disease | Essential Tremor

Belgium
KU Leuven

Completed

Characterization of Complex Pulse Shapes in Deep Brain Stimulation for Movement Disorders Using EEG and Local Field Potential Recordings (CHANNEL DBS)

Parkinson Disease | Essential Tremor

Belgium
Ablative Solutions, Inc.

Active, not recruiting

The TARGET BP OFF-MED Trial

Hypertension | Hypertension,Essential

Belgium, Germany, France, United Kingdom
sigma-tau i.f.r. S.p.A.

Completed

Efficacy of Rostafuroxin in the Treatment of Essential Hypertension

Essential Hypertension

Belgium
University Hospital, Ghent
Allergan

Terminated

Unicentric Comparing Study of Suction Curettage With Standard BOTOX Injection in the Treatment of Patients With Essential Axillar Hyperhidrosis: Comparing of Efficacy, Duration of Effectiveness, and Adverse Events.

Essential Axillary Hyperhidrosis

Belgium
Nina Hermans
University Hospital, Antwerp

Recruiting

Olive Polyphenols in Cardiovascular Prevention

Hypertension, Systolic

Belgium
Novartis

Completed

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

Essential Hypertension

Spain, United States, Belgium, Egypt, Germany, Poland, Slovakia, Turkey
University Ghent

Completed

Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension (Lisi-ped)

Primary Hypertension | Secondary Hypertension

Belgium
Boston Scientific Corporation

Recruiting

Deep Brain Stimulation (DBS) Retrospective Outcomes Study

Parkinson Disease | Dystonia | Essential Tremor

United States, Belgium, Germany
Orchestra BioMed, Inc
Medtronic

Recruiting

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT (BACKBEAT)

Hypertension | Hypertension, Systolic | Hypertension,Essential

United States, Czechia, Spain, Hungary, Belgium
University Ghent

Completed

Effects of Flavanoids in Essential Hypertension, Type 2 Diabetes and Healthy Persons

Vascular Complications, Diabetic

Belgium
Bayer

Completed

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension (DISTINCT)

Hypertension, Essential

Spain, Argentina, United States, Canada, Korea, Republic of, Italy, Russian Federation, South Africa, Ukraine, Belgium, Brazil, Lithuania, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
Daiichi Sankyo, Inc.
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

Essential Hypertension

Belgium, Germany, Netherlands, Slovakia
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
Sankyo Pharma Gmbh

Completed

Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension (OLMETREAT)

Essential Hypertension

France, Austria, Switzerland, Belgium, Germany, Italy, Netherlands, United Kingdom, Portugal
Brugmann University Hospital

Completed

Are the Fried Criteria Predictive of a Functional Decline in Older People With Solid Malignant Tumors?

Elderly Patients With a Solid Tumor

Belgium
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Erasme University Hospital

Terminated

Endomina as an Aid for Endoscopic Full Thickness Resection (EFTR)

Submucosal Tumor of Intestine

Belgium
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
AstraZeneca
Merck Sharp & Dohme LLC; Iqvia Pty Ltd

Completed

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. (IVIVC)

Malignant Solid Tumor

Belgium
Bayer

Completed

Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Hypertension

Germany, United States, Canada, Poland, United Kingdom, Belgium
Byondis B.V.

Completed

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875

Solid Tumor

France, Belgium
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
Constellation Pharmaceuticals

Active, not recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
Daiichi Sankyo, Inc.

Completed

Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension

Essential Hypertension

France, Poland, Ukraine, Belgium, Germany, Spain, Bulgaria, Romania, Denmark, Russian Federation, Netherlands, Austria, Slovakia, Czechia
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
iOmx Therapeutics AG

Recruiting

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

Solid Tumor

Spain, Belgium
Brugmann University Hospital

Completed

Diffusion MRI (Magnetic Resonance Imaging) Using ADC (Apparent Diffusion Coefficient) Histograms in the Evaluation of Adnexal Tumor Aggressiveness

Adnexal Tumor

Belgium
AstraZeneca

Completed

The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients. (SORT)

Essential Hypertension

India
European Organisation for Research and Treatment...

Completed

Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

Belgium, Netherlands
Jules Bordet Institute

Recruiting

Multidisciplinary Approach to Fatigue

Breast Cancer | Germ Cell Tumor

Belgium
Novartis Pharmaceuticals

Completed

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. (JUMP)

Myelofibrosis

Belgium, Colombia, Canada, Italy, Spain, Austria, Germany, Czechia, Thailand, Hungary, Greece, Argentina, Brazil, Israel, Russian Federation, Mexico, Portugal, South Africa, Tunisia, Slovakia, Saudi Arabia, Poland, Algeria, Ireland, Mor...
Sierra Oncology LLC - a GSK company

Completed

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Canada, Hungary, Israel, Spain, United States, Australia, Taiwan, Singapore, Germany, Italy, France, Belgium, New Zealand, Austria, United Kingdom, Denmark, Bulgaria, Poland, Czechia, Romania, Sweden
GlaxoSmithKline

Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

Neoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
University Hospital, Ghent

Completed

Trial of Adaptive 18F-FDG-PET Biological Intensity-modulated Radiotherapy (BG-IMRT) in Patients With Head and Neck Tumor

Head and Neck Tumor

Belgium
iTeos Therapeutics

Recruiting

New Formulation Study of Inupadenant (EOS100850) in Patients With Cancer

Solid Tumor, Adult

Belgium, United Kingdom
InteRNA

Terminated

First-in-Human Study of INT-1B3 in Patients With Advanced Solid Tumors

Solid Tumor

Netherlands, Belgium
Ziekenhuis Netwerk Antwerpen (ZNA)

Unknown

Screening Tools to Predict Treatment Outcome in Older Cancer Patients Who Are Undergoing Treatment

Unspecified Adult Solid Tumor, Protocol Specific

Belgium
Kling Biotherapeutics B.V.

Recruiting

Study of KBA1412 in Participants With Advanced Solid Malignant Tumors

Advanced Solid Tumor Malignancy

Belgium, Netherlands
Universitaire Ziekenhuizen KU Leuven

Terminated

18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors

Neuroendocrine Tumors | Neural Crest Tumor

Belgium
University Hospital, Ghent
University Ghent; Het Lezerscollectief

Completed

Evaluation of Bibliotherapy by Students and Patients With Cancer

Acute Leukemia | Advanced Solid Tumor

Belgium
MonTa Biosciences ApS
Allucent

Recruiting

Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours

Advanced Solid Tumor

Belgium, Denmark, Spain
Byondis B.V.

Recruiting

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Solid Tumor

Belgium, Italy, Netherlands, United Kingdom
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom

Clinical Trials on Essential Tremor in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations